Coya Therapeutics annual meeting: Garren elected director, auditor ratified

Coya Therapeutics, Inc.

Hideki Garren elected Class I director with 3,414,906 for, 405,471 withheld, 221,601 broker non-votes.
Ratification of Weaver & Tidwell as independent auditor received 4,008,651 for, 31,504 against, 1,823 abstain.
All proposals passed at the June 28, 2023 annual meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Coya Therapeutics, Inc. shareholders approved Ratification of appointment of Weaver and Tidwell, L.L.P. as independent registered public accounting firm at the 2023-06-28 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-28

Exact text from the filing

The proposal to ratify the appointment of Weaver and Tidwell, L.L.P. as the Company’s independent registered public accounting firm for our fiscal year ending December 31, 2023 was approved based upon the following votes: For Against Abstain 4,008,651 31,504 1,823

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Coya Therapeutics, Inc. shareholders approved Election of Hideki Garren, M.D., Ph.D. as a Class I director at the 2023-06-28 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-28

Exact text from the filing

The election of Hideki Garren, M.D., Ph.D. as a Class I director to hold office for a term of three years, until his successor is duly elected and qualified or he is otherwise unable to complete his term. The votes were cast for this matter were as follows: Nominee For Withheld Broker Non-Votes Hideki Garren, M.D., Ph.D. 3,414,906 405,471 221,601

View on SEC.gov

1183 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-178604

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.